Annexon, Inc.
NASDAQ:ANNXBiotechnology
-$0.04 today
- Market cap
- $568.53M
- Beta
- 1.18
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.01
Volume 2.88M
Average 2.56M
ANNX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Annexon, Inc.NASDAQ: ANNX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$43.19M, compared with -$53.82M a year earlier. Trailing-twelve-month EBITDA was -$193.41M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -51.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$43.19M+8.7% QoQ
- Last fiscal yearDec 2025
- -$204.04M-51.4% YoY
- LTMMar 2026
- -$193.41M-17.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +19.8% | +100.0% | +80.2 pp |
| 1 year | -51.4% | +100.0% | +151.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (204.04M) USD
- Year-over-year change
- -51.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (204.04M) | -51.4% |
| FY2024 | 2024-12-31 | (134.75M) | -2.0% |
| FY2023 | 2023-12-31 | (132.09M) | +5.5% |
| FY2022 | 2022-12-31 | (139.8M) | -9.1% |
| FY2021 | 2021-12-31 | (128.18M) | — |
EBITDA vs competitors
How ANNX compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -17.1% is the 8th highest of 11, against a peer median of -9.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $58.49M USD | +176.6% | — | 25.2% | |
| LTM Mar 2026 | $22.15M USD | +154.8% | — | 41.2% | |
| LTM Mar 2026 | -€42.36M EUR | +1.6% | — | 144435.8% | |
| LTM Mar 2026 | -CHF 64.45M CHF | -29.6% | — | 1740.8% | |
| LTM Mar 2026 | -$70.61M USD | -31.5% | — | 843.9% | |
| LTM Mar 2026 | -$74.72M USD | +35.0% | — | 129.0% | |
| LTM Jun 2026 | -$123.6M USD | -14.3% | — | 117.7% | |
| LTM Mar 2026 | -$193.41M USD | -17.1% | — | — | |
| FY2025 | -€300.7M EUR | -84.8% | — | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | -$442.87M USD | -9.5% | — | 5986.3% |
| LTM Sep 2026 | -$509.88M USD | -10.4% | — | 7186.4% | |
| Peer median (excluding ANNX) | — | -9.9% | — | 843.9% | |
Competitors are the stored peer set for ANNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 3.45M | 3.69M |
| Gross Profit | 0 | 0 | 0 | (3.45M) | (3.69M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 100.07M | 112.5M | 113.76M | 119.45M | 184.7M |
| Selling, General & Admin | 30.65M | 30.95M | 28.02M | 34.63M | 31.71M |
| Operating Expenses | 130.71M | 145.6M | 143.72M | 150.62M | 212.72M |
| Depreciation & Amortization | 2.14M | 2.15M | 2.15M | 3.45M | 2.65M |
| EBITDA | (128.18M) | (139.8M) | (132.09M) | (134.75M) | (204.04M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (130.71M) | (145.6M) | (143.72M) | (154.07M) | (216.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 390K | 3.65M | 9.49M | 15.87M | 9.72M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 390K | 3.65M | 9.49M | 15.87M | 9.72M |
| Income Before Tax | (130.32M) | (141.95M) | (134.24M) | (138.2M) | (206.69M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (130.32M) | (141.95M) | (134.24M) | (138.2M) | (206.69M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.34) | (2.60) | (1.77) | (1.01) | (1.34) |
| EPS (Diluted) | (3.34) | (2.60) | (1.77) | (1.01) | (1.34) |
| Weighted Avg Shares | 38.32M | 54.67M | 75.67M | 137.4M | 155.11M |
| Weighted Avg Shares (Diluted) | 38.32M | 54.67M | 75.67M | 137.4M | 155.11M |
Annexon, Inc.
NASDAQ:ANNX
Intrinsic Alpha fair value
Locked
Current Price
$3.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.